Shanxi Zhendong Pharmaceutical (300158.SZ) plans to invest 30 million yuan to establish a fund for investment in the biopharmaceutical field.

17:47 26/12/2025

Zhendong Pharmaceuticals (300158.SZ) issued an announcement to fully leverage the strength and resource advantages of professional investment institutions to integrate multiple resources in order to obtain long-term investment returns and enhance overall competitiveness. Without affecting the company's daily operations and development, and effectively controlling investment risks, the company recently signed a "Wenzhou Longmen Huixin No. 3 Entrepreneurship Investment Partnership Enterprise (Limited Partnership) Partnership Agreement" with Hainan Longmen Private Equity Fund Management Partnership Enterprise (Limited Partnership), Wen Nuo Yao, Beijing Xin Medical Consulting Co., Ltd., Shanghai Weinorun Cheng Pharmaceutical Technology Co., Ltd.

Shanxi Zhendong Pharmaceutical (300158.SZ) has announced that in order to meet strategic development needs, leverage the strength and resource advantages of professional investment institutions, integrate multiple resources to achieve long-term investment returns, enhance overall competitiveness, and to effectively control investment risks without affecting the company's daily operations and development, the company recently signed a "Wenzhou Longmen Huixin No. 3 Entrepreneurship Investment Partnership Enterprise (Limited Partnership) Partnership Agreement" with Hainan Longmen Private Equity Fund Management Partnership Enterprise (Limited Partnership), Wino Yao, Beijing Xin Yi Consulting Co., Ltd., and Shanghai Weino Runcheng Medical Technology Co., Ltd. According to the partnership agreement, the company, as a limited partner, will subscribe with its own funds for a capital contribution of 30 million RMB, with a contribution ratio of 28.5687%, and will bear limited liability up to the amount of the capital contribution. The main focus of the investment will be in the field of biopharmaceuticals.

Goldman Sachs Group, Inc. has raised the target price of Agios (AGIO.US) to 28 dollars, bullish on the prospects of the new drug Aqvesme for Mediterranean anemia.

Shenzhen Q&D Circuits (301628.SZ) is planning to issue convertible bonds to raise funds of up to 550 million yuan.

Wuhan Kotei Informatics (301221.SZ) took the lead in undertaking the acceptance of the major special project of science and technology in Wuhan City.

Goldman Sachs Group, Inc. has raised the target price of Agios (AGIO.US) to 28 dollars, bullish on the prospects of the new drug Aqvesme for Mediterranean anemia.

Shenzhen Q&D Circuits (301628.SZ) is planning to issue convertible bonds to raise funds of up to 550 million yuan.

Wuhan Kotei Informatics (301221.SZ) took the lead in undertaking the acceptance of the major special project of science and technology in Wuhan City.